Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease
Condition(s) studied
Study summary
This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend this imaging methodology to the heart.
The study will conduct additional PET/MRI scans of the heart in patients undergoing amyloid tracer PET scans for Alzheimer's evaluations. Each participant will also undergo an echocardiogram and a clinical examination of dementia.
This could potentially enhance diagnostic practices in both cardiac amyloidosis and Alzheimer's disease.
Eligibility
Primary outcome measure(s)
- Frequency of occurrence of cardiac amyloid deposits in patients with a diagnosis of Alzheimer's disease (overall) — through study completion, an average of 1 year
- Frequency of occurrence of cardiac amyloid deposits in relation to different disease manifestations (subdivided, for example, by clinical assessment of disease stage) — through study completion, an average of 1 year
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| University Hospital Essen | Essen | North Rhine-Westphalia | Recruiting |
More University Hospital, Essen trials in Germany
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07154394 on ClinicalTrials.gov ↗ ← All trials in Germany